These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 33917201)

  • 1. p53 Protein Isoform Profiles in AML: Correlation with Distinct Differentiation Stages and Response to Epigenetic Differentiation Therapy.
    Haaland I; Hjelle SM; Reikvam H; Sulen A; Ryningen A; McCormack E; Bruserud Ø; Gjertsen BT
    Cells; 2021 Apr; 10(4):. PubMed ID: 33917201
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hydroxyurea synergizes with valproic acid in wild-type p53 acute myeloid leukaemia.
    Leitch C; Osdal T; Andresen V; Molland M; Kristiansen S; Nguyen XN; Bruserud Ø; Gjertsen BT; McCormack E
    Oncotarget; 2016 Feb; 7(7):8105-18. PubMed ID: 26812881
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Epigenetic regulation of expression of retinoic acid receptor beta gene in leukemia cell].
    Meng YS; Ma XX; Meng XQ; Wei R; Liu W; Ai GW; Zhang YX
    Zhonghua Yi Xue Za Zhi; 2007 Dec; 87(48):3406-10. PubMed ID: 18476539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Flt3 Y591 duplication and Bcl-2 overexpression are detected in acute myeloid leukemia cells with high levels of phosphorylated wild-type p53.
    Irish JM; Anensen N; Hovland R; Skavland J; Børresen-Dale AL; Bruserud O; Nolan GP; Gjertsen BT
    Blood; 2007 Mar; 109(6):2589-96. PubMed ID: 17105820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. All-trans retinoic acid induces differentiation in primary acute myeloid leukemia blasts carrying an inversion of chromosome 16.
    Dembitz V; Lalic H; Tomic B; Smoljo T; Batinic J; Dubravcic K; Batinic D; Bedalov A; Visnjic D
    Int J Hematol; 2022 Jan; 115(1):43-53. PubMed ID: 34546543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic induction of p53 mediated apoptosis by valproic acid and nutlin-3 in acute myeloid leukemia.
    McCormack E; Haaland I; Venås G; Forthun RB; Huseby S; Gausdal G; Knappskog S; Micklem DR; Lorens JB; Bruserud O; Gjertsen BT
    Leukemia; 2012 May; 26(5):910-7. PubMed ID: 22064349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation analysis of p53 protein isoforms with NPM1/FLT3 mutations and therapy response in acute myeloid leukemia.
    Ånensen N; Hjelle SM; Van Belle W; Haaland I; Silden E; Bourdon JC; Hovland R; Taskén K; Knappskog S; Lønning PE; Bruserud Ø; Gjertsen BT
    Oncogene; 2012 Mar; 31(12):1533-45. PubMed ID: 21860418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The histone deacetylase inhibitor valproic acid alters sensitivity towards all trans retinoic acid in acute myeloblastic leukemia cells.
    Trus MR; Yang L; Suarez Saiz F; Bordeleau L; Jurisica I; Minden MD
    Leukemia; 2005 Jul; 19(7):1161-8. PubMed ID: 15902297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sequential valproic acid/all-trans retinoic acid treatment reprograms differentiation in refractory and high-risk acute myeloid leukemia.
    Cimino G; Lo-Coco F; Fenu S; Travaglini L; Finolezzi E; Mancini M; Nanni M; Careddu A; Fazi F; Padula F; Fiorini R; Spiriti MA; Petti MC; Venditti A; Amadori S; Mandelli F; Pelicci PG; Nervi C
    Cancer Res; 2006 Sep; 66(17):8903-11. PubMed ID: 16951208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Valproic acid triggers differentiation and apoptosis in AML1/ETO-positive leukemic cells specifically.
    Zapotocky M; Mejstrikova E; Smetana K; Stary J; Trka J; Starkova J
    Cancer Lett; 2012 Jun; 319(2):144-153. PubMed ID: 22261333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disease-stabilizing treatment based on all-trans retinoic acid and valproic acid in acute myeloid leukemia - identification of responders by gene expression profiling of pretreatment leukemic cells.
    Reikvam H; Hovland R; Forthun RB; Erdal S; Gjertsen BT; Fredly H; Bruserud Ø
    BMC Cancer; 2017 Sep; 17(1):630. PubMed ID: 28877686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular dissection of valproic acid effects in acute myeloid leukemia identifies predictive networks.
    Rücker FG; Lang KM; Fütterer M; Komarica V; Schmid M; Döhner H; Schlenk RF; Döhner K; Knudsen S; Bullinger L
    Epigenetics; 2016 Jul; 11(7):517-25. PubMed ID: 27309669
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long non-coding RNA HOTAIR regulates myeloid differentiation through the upregulation of p21 via miR-17-5p in acute myeloid leukaemia.
    Hu L; Liu J; Meng Y; Zheng H; Ding C; Wang H; Charwudzi A; Li M; Li J; Zhai Z; Xiong S
    RNA Biol; 2021 Oct; 18(10):1434-1444. PubMed ID: 33241756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isocitrate dehydrogenase 1 mutations prime the all-trans retinoic acid myeloid differentiation pathway in acute myeloid leukemia.
    Boutzen H; Saland E; Larrue C; de Toni F; Gales L; Castelli FA; Cathebas M; Zaghdoudi S; Stuani L; Kaoma T; Riscal R; Yang G; Hirsch P; David M; De Mas-Mansat V; Delabesse E; Vallar L; Delhommeau F; Jouanin I; Ouerfelli O; Le Cam L; Linares LK; Junot C; Portais JC; Vergez F; Récher C; Sarry JE
    J Exp Med; 2016 Apr; 213(4):483-97. PubMed ID: 26951332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 5-aminoimidazole-4-carboxamide ribonucleoside induces differentiation in a subset of primary acute myeloid leukemia blasts.
    Dembitz V; Lalic H; Kodvanj I; Tomic B; Batinic J; Dubravcic K; Batinic D; Bedalov A; Visnjic D
    BMC Cancer; 2020 Nov; 20(1):1090. PubMed ID: 33176741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dasatinib accelerates valproic acid-induced acute myeloid leukemia cell death by regulation of differentiation capacity.
    Heo SK; Noh EK; Yoon DJ; Jo JC; Park JH; Kim H
    PLoS One; 2014; 9(2):e98859. PubMed ID: 24918603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting AML1/ETO-histone deacetylase repressor complex: a novel mechanism for valproic acid-mediated gene expression and cellular differentiation in AML1/ETO-positive acute myeloid leukemia cells.
    Liu S; Klisovic RB; Vukosavljevic T; Yu J; Paschka P; Huynh L; Pang J; Neviani P; Liu Z; Blum W; Chan KK; Perrotti D; Marcucci G
    J Pharmacol Exp Ther; 2007 Jun; 321(3):953-60. PubMed ID: 17389244
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Time- and residue-specific differences in histone acetylation induced by VPA and SAHA in AML1/ETO-positive leukemia cells.
    Barbetti V; Gozzini A; Cheloni G; Marzi I; Fabiani E; Santini V; Dello Sbarba P; Rovida E
    Epigenetics; 2013 Feb; 8(2):210-9. PubMed ID: 23321683
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epigenetic priming of AML blasts for all-trans retinoic acid-induced differentiation by the HDAC class-I selective inhibitor entinostat.
    Blagitko-Dorfs N; Jiang Y; Duque-Afonso J; Hiller J; Yalcin A; Greve G; Abdelkarim M; Hackanson B; Lübbert M
    PLoS One; 2013; 8(10):e75258. PubMed ID: 24116031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epigenetic silencing of ZCCHC10 by the lncRNA SNHG1 promotes progression and venetoclax resistance of acute myeloid leukemia.
    Zhou H; Zhang Q; Huang W; He C; Zhou C; Zhou J; Ning Y
    Int J Oncol; 2023 May; 62(5):. PubMed ID: 37052262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.